Intellia Therapeutics, Inc.
NTLA
$9.52
-$2.80-22.73%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 52.86M | 45.57M | 57.88M | 43.09M | 45.97M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 52.86M | 45.57M | 57.88M | 43.09M | 45.97M |
| Cost of Revenue | 429.22M | 449.12M | 452.54M | 444.64M | 434.96M |
| Gross Profit | -376.36M | -403.55M | -394.66M | -401.56M | -388.99M |
| SG&A Expenses | 135.66M | 137.52M | 139.60M | 136.15M | 135.06M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 564.88M | 586.64M | 592.14M | 580.79M | 570.01M |
| Operating Income | -512.02M | -541.07M | -534.26M | -537.71M | -524.05M |
| Income Before Tax | -480.19M | -525.91M | -519.02M | -522.28M | -508.80M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -480.19 | -525.91 | -519.02 | -522.28 | -508.80 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -480.19M | -525.91M | -519.02M | -522.28M | -508.80M |
| EBIT | -512.02M | -541.07M | -534.26M | -537.71M | -524.05M |
| EBITDA | -501.87M | -530.80M | -523.98M | -527.52M | -514.18M |
| EPS Basic | -4.69 | -5.23 | -5.25 | -5.45 | -5.48 |
| Normalized Basic EPS | -2.89 | -3.09 | -3.07 | -3.21 | -3.25 |
| EPS Diluted | -4.69 | -5.23 | -5.25 | -5.45 | -5.48 |
| Normalized Diluted EPS | -2.89 | -3.09 | -3.07 | -3.21 | -3.25 |
| Average Basic Shares Outstanding | 410.09M | 403.33M | 395.33M | 383.94M | 371.58M |
| Average Diluted Shares Outstanding | 410.09M | 403.33M | 395.33M | 383.94M | 371.58M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |